Triple negative breast cancer accounts for 15% of cases but causes a disproportionate number of deaths. Learn about symptoms ...

Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different ...

Metastatic breast cancer is complex, requiring holistic care and ongoing treatment, with varying prognosis depending on ...

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of disease ...

The broadcaster, 53, was diagnosed with breast cancer in August 2022 and underwent gruelling chemotherapy, as well as a double mastectomy, before receiving the all-clear in 2023.

Ciara Foskin’s diagnosis came out of the blue. She is part of a small cohort of women under 50 who develop triple-negative ...

Testing for BRCA mutations linked to breast and ovarian ... could lead to the identification of thousands more gBRCAm HR-positive early breast cancer patients in France, Germany, Italy, Spain ...

Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) ...

Genetic testing helps identify hereditary cancer risks, with 5-10% of cancers caused by inherited mutations. Early detection ...

Hope for aggressive breast cancer. Survivors and doctors discuss breakthroughs, fears, and the need for inclusive research.

In metastatic triple-negative breast cancer, sacituzumab govitecan was effective and tolerable in the real-world setting.